SCHEMBL8540746

SCHEMBL8540746

BrCc1cc(-c2ccccc2)ccc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
MAPK1 P28482 2/20 0.44
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
DCLRE1A Q6PJP8 1/20 0.41
DCLRE1B Q9H816 1/20 0.41
BACE1 P56817 1/20 0.40
ALOX5 P09917 1/20 0.39
CYP1A2 P05177 1/20 0.39
MEN1 O00255 2/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
HTT P42858 2/20 0.38
KMT2A Q03164 2/20 0.38
PTPN1 P18031 1/20 0.38
GSK3B P49841 1/20 0.38
APAF1 O14727 1/20 0.38
NPC1 O15118 1/20 0.38
THRB P10828 1/20 0.38
XBP1 P17861 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20696572 1.00 ALDH1A1 (0.44) ALDH1A1MAPK1CRHBPCRHR2DCLRE1A
SCHEMBL15832277 0.83 CRHBP (0.47) ALDH1A1MAPK1CRHBPCRHR2DCLRE1A
SCHEMBL5160117 0.83 DCLRE1A (0.43) ALDH1A1MAPK1DCLRE1ADCLRE1BBACE1
SCHEMBL455838 0.82 DCLRE1A (0.43) ALDH1A1MAPK1CRHBPCRHR2DCLRE1A
SCHEMBL18076562 0.82 BACE1 (0.46) ALDH1A1MAPK1CRHBPCRHR2DCLRE1A
SCHEMBL6772798 0.78 ESR2 (0.47) ALDH1A1MAPK1DCLRE1ADCLRE1BBACE1
SCHEMBL6772346 0.78 GAA (0.42) ALDH1A1MAPK1DCLRE1ADCLRE1BBACE1
SCHEMBL27403956 0.75 CRHBP (0.56) ALDH1A1MAPK1CRHBPCRHR2ALOX5
SCHEMBL8684504 0.75 ADRB2 (0.40) NPC1RAB9ASMN1; SMN2
SCHEMBL8536565 0.74 CRHBP (0.39) ALDH1A1MAPK1CRHBPCRHR2DCLRE1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220384735-A1 PERI-CONDENSED HETEROCYCLIC COMPOUNDS AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2022-12-01 US disclosed
WO-2021053046-A1 PERI-CONDENSED HETEROCYCLIC COMPOUNDS AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2021-03-25 WO disclosed
EP-3271320-B1 COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS VECTUS BIOSYSTEMS LTD (AU) 2019-10-23 EP disclosed
US-10035775-B2 Compositions for the treatment of fibrosis and fibrosis-related conditions VECTUS BIOSYSTEMS LIMITED (AU) 2018-07-31 US disclosed
US-20180072682-A1 COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS VECTUS BIOSYSTEMS LIMITED (AU) 2018-03-15 US disclosed
EP-0857171-A2 IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 1998-08-12 EP disclosed
WO-1997015555-A2 IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 1997-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10035775-B2 Compositions for the treatment of fibrosis and fibrosis-related conditions MMP1, COL1A1, COL2A1 ALDH1A1 800/4885MAPK1 2260/4885CRHBP 2573/4885
US-20180072682-A1 COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND FIBROSIS-RELATED CONDITIONS MMP1, COL1A1, COL2A1 ALDH1A1 800/4885MAPK1 2260/4885CRHBP 2573/4885
US-20220384735-A1 PERI-CONDENSED HETEROCYCLIC COMPOUNDS AS MATERIALS FOR ELECTRONIC DEVICES KCNH1, NES, KCNC1 ALDH1A1 828/4885MAPK1 1324/4885CRHBP 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.